Medical guideline

首页肿瘤学指南检索结果

检索结果

按发表年份

共搜索到1条与There Is No Evidence-based Indication for Radiation Treatment in the Primary Setting (adjuvant/neoadjuvant Or Definitive) of Renal Cell Cancer in the Future Stereotactic Radiotherapy Should Have a Stronger Role in the Treatment of Medically Inoperable Patients with Primary Renal Cell Cancer and Especially in the Setting of Oligometastasis有关的结果

German S3 Guideline for Renal Cell Carcinoma : Presentation and Discussion of Essential Aspects for the Radiation Oncologist

2018年发布于 Strahlenther Onkol 194卷第1期 所属人体系统：泌尿 | 肾癌

无

Purpose: We Aim to Introduce and Discuss the Statements and Recommendations of the German S3 Guideline on Renal Cell Cancer for Daily Practice of Radiation Oncologists Methods: This Report Comprises Indication Treatment Decision Dose Prescription and Current Literature Including Treatment of Oligometastatic Disease Results: According to Different Stages of the Disease and the Structure of the Guideline We Focus on Five Treatment Situations and Recommendations for Decision Making: (1) Neo-/adjuvant Treatment Before Or after Nephrectomy: No Indication for Radiotherapy (2) Small Renal Mass: Stereotactic Ablative Radiotherapy Is Currently Seen as Experimental Option due to Small Patient Numbers Reported in the Literature However Local Tumor Control Achieved by SBRT Appears Favourable with >90% at 2 Years (3) Oligometastasis: Radiation Treatment with Higher Local Doses Or Stereotactic Treatment Is Possible after Interdisciplinary Discussion Indications for Palliative (4) and Symptomatic Treatment (5) Are Not Different Compared to Other Tumor Entities Conclusion: Currently There Is No Evidence-based Indication for Radiation Treatment in the Primary Setting (adjuvant/neoadjuvant Or Definitive) of Renal Cell Cancer in the Future Stereotactic Radiotherapy Should Have a Stronger Role in the Treatment of Medically Inoperable Patients with Primary Renal Cell Cancer and Especially in the Setting of Oligometastasis
指南简介 原文链接